Notably, the mutations in all BSOr variants mapped to capsid protein VP1 and VP3 (Figure 3A), and none to 2C ATPase
Although Medicare doesnt cover Wegovy for weight loss as of March 2025, legislators are trying to change that with the Treat and Reduce Obesity Act of 2023
In addition to these approved uses, clinical trials in people with specific health conditions have shown that GLP-1s offer additional benefits, such as: Reducing the risk of heart attack and stroke Slowing kidney disease progression Treating moderate-to-advanced liver fibrosis Treating moderate-to-severe obstructive sleep apnea Also, semaglutide (Wegovy) is FDA-approved for chronic weight management in adolescents age 12 and older with obesity
After the initial injection, Voss moved to the next step
It's a testament to the importance of clinical observation, patient advocacy, and the willingness to think outside conventional paradigms
[DOI] [PubMed] [Google Scholar] 150.Musial C., Kuban-Jankowska A., Gorska-Ponikowska M